Select Page

Why map the pharmome? (Part 1)

by William Busa | Sep 13, 2024

‘Mapping the pharmome’ is a new scientific discipline, championed by EvE Bio, the long-term goal of which is to identify all of the unintended molecular targets of today’s (and tomorrow’s) drugs, in order to (1) minimize future drugs’ side effects, (2) provide AI-based drug development tools with better training and validation data, (3) systematically identify opportunities to inexpensively repurpose old drugs for new indications, and more.


Part 1: For safer drugs

A question frequently posed regarding pharmome mapping goes something like:

“Don’t pharmaceutical companies already do that? Don’t they test each new drug to ensure it won’t act on any gene products other than the drug’s intended therapeutic target (so-called ‘off-targets’), in order to avoid ‘off-target side effects?’”

The short answer is “yes, but no.” Yes, pharmas do a bit of such ‘secondary pharmacology profiling;’ but no, not nearly enough (we think). A recent report in Nature Reviews Drug Discovery provides an inside look at this question, and helps to illustrate the importance of our work at EvE.

The report’s authors, luminaries in the discipline of safety pharmacology, surveyed 18 major pharmaceutical companies regarding the numbers and identities of potential off-targets against which they test each and every one of their new drug candidates in the interest of safety. The numbers ranged from a low of 11 to a high of 104 potential off-targets routinely profiled per company, with a median of about 45. Interestingly, the industry’s opinions regarding which potential off-targets to screen vary widely. The total number of potential off-targets screened, across the universe of all 18 pharmas, was 763, yet only 12% of them were screened by more than a third of those companies.

Such numbers pale in comparison to the total number of protein-coding genes in the human genome (roughly 20,000) or even merely the subset of those that are widely considered ‘druggable’ (i.e., capable of being modulated by drug-like small molecules: about 4,500). Thus, today’s routine secondary pharmacology profiling only just scratches the surface, focusing on a handful of the most notorious bad actors while leaving other off-targets unidentified (and, thus, unavoided in future drug development), consigning patients to the near inevitability of off-target side effects.

Avoiding off-target side effects wherever possible is valuable not merely because side effects are unpleasant, but more importantly because they can be so disabling as to present a grave challenge to patient compliance, and thus to therapeutic efficacy, as has been well documented in, for example, the case of first-generation HIV drugs. Side effects so severe that their quality of life impacts can and do compromise patient compliance are all too common in disorders including depression, epilepsy, autoimmune diseases like multiple sclerosis and lupus, cancer, infectious diseases, and many more.

The logic behind the pharma industry’s relatively parsimonious triage, when searching for off-targets, is driven by business considerations regarding resource availability (time, money, and manpower). For, as the authors of the Nature Reviews report note:

Inclusion of [additional] targets must consider resources required to add targets to any profiling panel, which may be prohibitive [….] The number of targets included in a panel is often a balance between confidence in overall findings with respect to off-target liability, and resource constraints.

Plainly put, for-profit pharmaceutical companies have investors’ earnings expectations to meet, and developing and running thousands of distinct assays for potential off-targets that may or may not present actual safety issues falls well outside those expectations. Nonetheless, likely every pharma has accumulated some body of safety pharmacology data over the years, spanning multiple targets of interest and numerous drugs. A rare look into such legacy data was provided last year in a report by scientists at the Swiss pharmaceutical giant, Novartis, who presented data collected “over a multi-year period” profiling drug/target interactions across a median of about 800 drugs per target and 105 gene product targets – roughly 2% of the ‘druggable genome’.

Lest we be too quick to blame the profit motive for our limited visibility into drugs’ off-targets today, it is good to note as well that the challenge of systematically cataloging drug/off-target interactions remains largely unaddressed by academic and government researchers, as well. Science-based public goods like pharmome-mapping, which are both difficult or impossible to monetize and unlikely to compete for government research funding, are precisely why Focused Research Organizations like EvE Bio exist. Learn more about FROs from our parent organization, Convergent Research.